About

Narvitas Medical Devices Limited is a UK-based international medical device company that designs, develops, manufactures and distributes medical devices which are new entrants into large underserved segments of health care. The company was founded in February 2014 to establish an operating entity for the production and distribution of medical device technology which are the property of Narvitas. The company is pre-revenue and ready to go commercial Q1 2016.


The initial product platform is the LapDome Laparoscopic surgery access device which addresses an unmet need and is  designed to provide a more simplified, eloquent, safer and faster entry into the abdominal cavity. Laparoscopic surgery enjoys global acceptance; it is the second largest medical segment with close to 13 million procedures performed annually. As a surgical device the LapDome can be utilized on every laparoscopic procedure. The LapDome is CE-Mark certified and ready to go commercial Q1 2016.

The LapDome is a provisional patent filed design incorporating a moulded plastic dome with a port for attachment of the suction system and an injection port for the insertion of surgical equipment, such as the Veress needle. The device is placed in the centre of the abdomen, a suction hose attached to the suction port, and negative pressure suction is applied. The abdomen immediately rises and, as the as the inert gas is delivered, the Veress needle is inserted into the created space, with no risk of injuring a vital organ, inert gas is delivered to replace the negative pressure and the surgery can commence.

The current standard of care in laparoscopic access procedures has not changed in 30 years. Our LapDome platform is superior to the current standard of care in terms of clinical utility, patient care and economics.

The LapDome stands out as the new standard of care in laparoscopic surgery. It represents a new and significant competitive advantage. It is designed to address shortcomings in laparoscopic surgery access. It features single surgical operator use, reduces time for insufflations, minimises need for trocar incisions, reduces risk of injury to underlying organ & vessels, shorter patient recovery time & less narcotic use, reduced OR time and reduced therapy recovery time and lower complication rate.

Given the global acceptance of laparoscopic surgery as the standard of care, there is little limitation as to where the LapDome portfolio of products may be marketed and sold. Narvitas will initially launch the LapDome product platform Q1 2016 in the British isles, Benelux, Germany and Switzerland. This will be followed by a robust marketing expansion strategy in the rest of Europe and the main laparoscopic markets in the Middle East and Latin America.

The US market still stands alone as the single largest opportunity in medical devices. While international markets remain dominated by the traditional distributor model, the US market is primarily served through the direct sales operations of multi-national manufacturers. Launching of the US program is scheduled for Q4 2016 following FDA approval.

The next product in the pipeline is the EpiDome device which is scheduled to follow the launching of the LapDome. It focuses on epidural anesthesia procedures by applying Dome technology to a currently manual procedure to make it more simplified while reducing waste. Epidural anesthesia is the most popular method of pain relief during labor. The global market is huge and expanding. Total worldwide annual births are estimated at 130 million. In the United States alone 60% of childbirths receive epidural anesthesia and the trend is growing.

NARVITAS’ management comprises a team of seasoned executives with notable, successful track records in the medical, financial and international trade industries, committed to delivering results. We leverage the experience and network of top professionals accumulated over 30 years to bring value and market savvy to our partners and investors. All members of the management team are shareholders and founding members of the company and engaged in this project on a full-time basis.